IMTX
Immatics N.V.
IMTX has lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over IMTX overall, supported by stronger fundamentals and stronger modeled upside.
IMTX Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Weak | |
| Strong |
IMTX's balance sheet is currently strong, but its revenue, profitability and cash flow are under pressure.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
IMTX PE Valuation
IMTX has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
IMTX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong decline | |
| -- | |
| Limited | |
| Low |
Analysts expect IMTX's losses to grow, with revenue declining. However, they disagree widely on these estimates.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
IMTX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$1.77 | -$1.15 |
| Q1 2026 | -$1.90 | -$1.73 |
| Q4 2025 | -$1.79 | -1153% |
| Q3 2025 | -$0.97 | -$0.28 |
| Q2 2025 | -$0.62 | +$0.30 |
| Q1 2025 | -$0.17 | +$0.92 |
| Q4 2024 | $0.17 | +$1.51 |
| Q3 2024 | -$0.69 | +$0.50 |
IMTX is still losing money, but far less than before: $1.77 per share over the past year, against $4.09 at its worst in mid-2021.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over IMTX on earnings quality, reporting a profit while its opponent remains loss making.
IMTX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $10.2M | +93% |
| Q1 2026 | $8.5M | -59% |
| Q4 2025 | $22M | -65% |
| Q3 2025 | $5.8M | -90% |
| Q2 2025 | $5.3M | -75% |
| Q1 2025 | $20.6M | -39% |
| Q4 2024 | $62.5M | +253% |
| Q3 2024 | $56.2M | +753% |
IMTX's revenue is recovering but still below its 2022 peak: $10M last quarter, up 93% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -735% | +387 points |
| Q1 2026 | -868% | -678 points |
| Q4 2025 | -197% | -198 points |
| Q3 2025 | -1053% | -1054 points |
| Q2 2025 | -1122% | -980 points |
| Q1 2025 | -190% | -146 points |
| Q4 2024 | 1.6% | +176 points |
| Q3 2024 | 1% | +562 points |
IMTX's operating margin was −735% last quarter, up 387 points from the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over IMTX on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over IMTX on profitability, with a higher operating margin.
IMTX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$69M | -$23.8M |
| Q1 2026 | -$48.3M | -$6.9M |
| Q4 2025 | -$65.1M | +$1.8M |
| Q3 2025 | -$50.9M | -$10.3M |
| Q2 2025 | -$45.1M | -$5.1M |
| Q1 2025 | -$41.5M | +$5.2M |
| Q4 2024 | -$66.9M | -186% |
| Q3 2024 | -$40.6M | +$557.7K |
IMTX has burned cash in most quarters: −$233M over the past year, against −$194M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over IMTX on cash generation, producing positive trailing cash flow while its opponent burns cash.
IMTX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.5% | +2M shares |
| 1 year | +12% | +15.1M shares |
| 3 years | +77% | +59.4M shares |
| 5 years | +117% | +73.8M shares |
| Available history | +117% | +73.8M shares |
IMTX has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
IMTX hasn't bought back shares in the past year.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
IMTX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2024 | -6.4x | Net Cash |
| Q4 2022 | -3.6x | Net Cash |
| Q3 2022 | -7.9x | Net Cash |
| Q2 2022 | -13.0x | Net Cash |
| Q1 2022 | -20.1x | Net Cash |
IMTX has more cash than debt.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
IMTX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 33.4 | Neutral |
| Stochastic | 11.5 | Oversold |
IMTX's weekly RSI is 33 (neutral) and its Stochastic is 12 (oversold).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
IMTX PE vs Healthcare Sector
| Metric | IMTX | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
IMTX has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
IMTX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $7.19 | 9.3% below |
| 20 week MA | $8.45 | 23% below |
| 50 week MA | $9.48 | 31% below |
| 100 week MA | $7.91 | 18% below |
| 200 week MA | $9.15 | 29% below |
IMTX is in a downtrend: it's below all five of its weekly moving averages, and 29% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over IMTX on trend strength, trading above more of its moving averages.
IMTX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $10.4 | $9.99 | -3.9% |
| 2021 | $9.99 | $13.0 | +30% |
| 2022 | $13.0 | $8.51 | -34% |
| 2023 | $8.51 | $10.5 | +24% |
| 2024 | $10.5 | $7.13 | -32% |
| 2025 | $7.13 | $10.2 | +43% |
| 2026 YTD | $10.2 | $6.52 | -36% |
IMTX has finished lower in three of the last six years. It's down 36% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over IMTX on returns for 2026, with the stronger performance.